Trial Profile
A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone resorption; Metabolic bone diseases; Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Sponsors Amgen
- 13 Nov 2013 New trial record